Archive for the ‘clinical study retractions’ Category
Should scientific misconduct be handled by the police? It’s fraud week at Nature and Nature Medicine
Those are three highlights from a number of pieces that have appeared in Nature and Nature Medicine in the past few weeks. Not surprisingly, there are common threads, so join us as we follow the bouncing ball. Read the rest of this entry »
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.
A group of anesthesiology researchers in China has lost their 2011 paper in Der Anaesthesist because, well, the article wasn’t theirs to begin with.
The paper, “Different anesthesia methods for laparoscopic cholecystectomy,” came from authors at the 309th Hospital of PLA, in Beijing, who purported to report on a randomized trial of 68 patients undergoing laparoscopic colon surgery with either general or spinal (that is, a nerve block) anesthesia. According to the abstract:
Read the rest of this entry »
The European Journal of Nuclear Medicine and Molecular Imaging has an interesting exchange of retraction-related notices in its pages.
The article, “Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging,” appeared in 2011 and was written by Benjamin Hayempour and Abass Alavi, one of the pioneers in PET imaging.
According to the retraction notice:
This article has been withdrawn at the request of the Editor-in-Chief of European Journal of Nuclear Medicine and Molecular Imaging owing to the unexplained close similarity of some passages to parts of a previous publication [Rushing SE, Langleben DD. Relative function: Nuclear brain imaging in United States courts. J Psychiatry Law 2011; 39 (winter): 567–93].
Read the rest of this entry »
The retraction notice for the paper, “Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome,” fairly bristles with indignation: Read the rest of this entry »
Two cancer researchers who hold a patent on a particular pathway that might be a target for new drugs — and one of whom leads a company that is studying those potential drugs — have retracted two related papers in the Journal of Biological Chemistry (JBC).
The notices for “Kinase suppressor of Ras signals through Thr269 of c-Raf-1“ and “The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK,” which share H. Rosie Xing and Memorial Sloan-Kettering’s Richard Kolesnick as authors, say the same thing: Read the rest of this entry »
The Journal of Clinical Anesthesia has a retraction of a 2006 paper by a group from Columbia University that, to our minds, is the poster child for how not to handle such things.
The article, “Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery,” was written by Robert J. Frumento, Helene G. Logginidou, Staffan Wahlander, Gebhard Wagener, Hugh R. Playford and Robert N. Sladen, who now is chief of critical care at the institution. The paper has been cited 30 times, according to Thomson Scientific’s Web of Knowledge.